Clinical Trial of Allogeneic Mesenchymal Stem Cell Therapy for Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients Unresponsive to Rituximab and Intravenous Immunoglobulin

Clinical trials of biologic agents for chronic active antibody-mediated rejection (CAMR) in kidney transplant recipients (KTRs) have been disappointing. We performed a clinical trial of mesenchymal stem cell (MSC) treatment in KTRs with CAMR unresponsive to rituximab and intravenous immunoglobulin....

Descripción completa

Detalles Bibliográficos
Autores principales: Ban, Tae Hyun, Lee, Sua, Kim, Hyung Duk, Ko, Eun Jeong, Kim, Bo-Mi, Kim, Kyoung-Woon, Chung, Byung Ha, Yang, Chul Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892211/
https://www.ncbi.nlm.nih.gov/pubmed/33628269
http://dx.doi.org/10.1155/2021/6672644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892211/
https://www.ncbi.nlm.nih.gov/pubmed/33628269
http://dx.doi.org/10.1155/2021/6672644

Ejemplares similares